{"title":"[A Therapeutic Strategy Targeting Virus-Antigen in Cancer Treatment].","authors":"Tomohiro Enokida","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Evidence has increasingly highlighted the potential of viral antigens as ideal treatment targets for virus-related cancers, primarily due to their exclusive expression on cancer cells and capacity to stimulate robust immune responses and eliminate malignant cells effectively. Innovative approaches such as vaccines tailored to stimulate an immune response, engineered T-cell therapies designed to evidently recognize and destroy cancer cells, and drug delivery methods for selectively expanding and activating virus-antigen-specific T-cells have shown great promise. Numerous studies have indicated that these virus-targeted therapies have potentially improved patient prognostic outcomes with acceptable toxicities. Future research is essential to optimize these approaches and lead them to clinical practice to achieve complete eradication of virus-related cancers.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"294-299"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Evidence has increasingly highlighted the potential of viral antigens as ideal treatment targets for virus-related cancers, primarily due to their exclusive expression on cancer cells and capacity to stimulate robust immune responses and eliminate malignant cells effectively. Innovative approaches such as vaccines tailored to stimulate an immune response, engineered T-cell therapies designed to evidently recognize and destroy cancer cells, and drug delivery methods for selectively expanding and activating virus-antigen-specific T-cells have shown great promise. Numerous studies have indicated that these virus-targeted therapies have potentially improved patient prognostic outcomes with acceptable toxicities. Future research is essential to optimize these approaches and lead them to clinical practice to achieve complete eradication of virus-related cancers.